AI heart monitor tested for cancer drug safety
NCT ID NCT05623397
Summary
This study tested whether a new artificial intelligence (AI) tool could accurately measure a specific heart rhythm interval (QTc) from electrocardiograms (ECGs). The research involved 70 women with breast cancer who were starting treatment with the drug ribociclib, which requires heart monitoring. The main goal was to see if the AI tool could perform as well as the current best manual method, potentially allowing for simpler, more accessible heart monitoring devices.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CIC - Hôpitaux Universitaires Pitié Salpêtrière, Paris, FRANCE
Paris, PARIS, 75651, France
-
Groupe Ambroise Paré, Hartmann
Neuilly-sur-Seine, 92200, France
-
Hôpital Tenon
Paris, 75020, France
-
Institut Gustave Roussy
Villejuif, 94805, France
Conditions
Explore the condition pages connected to this study.